Navigation Links
DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)
Date:8/27/2009

CUPERTINO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) today reported that it has signed an exclusive long term excipient supply agreement with respect to REMOXY(R) with King Pharmaceuticals, Inc. (NYSE: KG). This agreement stipulates the terms and conditions under which DURECT will supply to King, based on DURECT's manufacturing cost plus a specified percentage mark-up, two key excipients used in the manufacture of REMOXY.

(Logo:http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

"While we've been providing King with these key excipients starting in 2008, we're pleased to have now entered into this long term arrangement with King that formalizes the details of our supply agreement," stated James E. Brown, DURECT's President and CEO. "Given King's strong presence in pain management and commitment to be a leader in the development of products designed to reduce the potential for misuse and abuse, we look forward to supporting King's efforts to bring REMOXY to market."

REMOXY, based on DURECT's ORADUR(TM) technology, is an investigational drug that is a unique, controlled release formulation of oxycodone for moderate-to-severe chronic pain designed to reduce potential risks of unintended use. In mid-2008, an NDA for REMOXY was accepted by the FDA and was granted Priority Review. In December 2008, the FDA issued a Complete Response Letter related to REMOXY. In July 2009, King Pharmaceuticals met with the FDA to discuss the Complete Response Letter and King Pharmaceuticals has stated that it anticipate
'/>"/>

SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
2. DURECT Corporation Announces Second Quarter 2009 Financial
3. DURECT to Present at the BMO Capital Markets Healthcare Conference
4. DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call
5. DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
6. DURECT Corporation Invites You to Join its First Quarter 2009 Earnings Conference Call
7. DURECT to Participate in Cowen and Company Healthcare Conference
8. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
9. DURECT Corporation Invites You to Join Its Fourth Quarter 2008 Earnings Conference Call
10. DURECT Corporation to Participate in Upcoming Healthcare Conferences
11. DURECT Corporation to Participate in Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... October 31, 2014 This Method ... amazing health effects for practitioners. , The ... Doctor of Science and Movement specializing in physical ... to pelvic floor reeducation that traditional abdominal exercises ... Diastasis Recti, Prolepses, etc. , The Hipopressives exercises ...
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Surgery for low back ... in the United States you live, a new report ... low back pain at some point in their lives, ... medical care for a spine problem," co-author Brook Martin, ... Practice, said in a college news release. In ...
(Date:10/31/2014)... say that either they or a family member have ... latest issue of The Gerontological Society of America,s ... which goes on to show that Americans strongly support ... end-of-life health care wishes. , This PP&AR , ... features 12 articles that present new ways of understanding ...
(Date:10/31/2014)... Urban Hydroponics, Inc. (OTCQB:URHY), a Nevada ... has signed a Binding Letter of Intent (LOI) to ... sector - Urban Cultivator Inc. (“Urban Cultivator”), BC Northern ... Inc. (“W3 Metal” and together with Urban Cultivator and ... the LOI and an earlier non-binding term sheet, Urban ...
(Date:10/31/2014)... Miami, FL (PRWEB) October 31, 2014 ... recently volunteered his hair restoration services to transform the ... part of the American Academy of Facial Plastic and ... donated his time to restore the facial hair Jones ... , The pro-bono hair restoration procedure, valued ...
Breaking Medicine News(10 mins):Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Advance directives can benefit patients, families, and health care system 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 4Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 5Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2
... $18 million research program headed by Washington University ... and diagnostic tools for heart and lung diseases ... Heart, Lung, and Blood Institute, will fund five ... collaborating,institutions: Texas A&M University, University of Texas Southwestern ...
... The Alzheimer,s Association has awarded a three-year, $200,000 ... The University of Texas Health Science Center at Houston ... Alzheimer,s disease. "The main goal of this project ... such as a blood test that can tell people ...
... A team of researchers led by a Michigan State University ... for breast cancer in young women, focusing on growth, diet, ... The five-year study, funded by the National Institutes ... of Human Medicine,s Department of Epidemiology, will include the largest ...
... traumatic event a car accident, a physical or ... many as 1 in 5 children will develop Posttraumatic ... helps improve communication between child and caregiver, such as ... skills, was able to prevent chronic and sub-clinical PTSD ...
... Minn. -- In the largest, most modern, single-institution ... a long-term data registry for survival rates of ... for localized prostate cancer. The findings are being ... American Urological Association,s 84th Annual Meeting in Chicago. ...
... HealthDay Reporter , TUESDAY, Sept. 28 (HealthDay News) -- ... proteins may indicate the presence of prostate cancer more accurately ... The test, which has thus far only been assessed ... fewer false-positive results than the prostate specific antigen (PSA) test, ...
Cached Medicine News:Health News:WUSTL awarded $18 million to treat heart, lungs with nanotechnology 2Health News:WUSTL awarded $18 million to treat heart, lungs with nanotechnology 3Health News:MSU researcher awarded $14 million to identify breast cancer risk factors 2Health News:After traumatic event, early intervention reduces odds of PTSD in children by 73 percent 2Health News:Surgery offers long-term survival for early stage prostate cancer patients 2Health News:Experimental Test May Spot Prostate Cancer Earlier, More Accurately 2Health News:Experimental Test May Spot Prostate Cancer Earlier, More Accurately 3
(Date:10/31/2014)... Oct. 31, 2014  Zebra Imaging, Inc., the ... announced today a strategic partnership with the Zygote ... 3D anatomy and biomedical models for animation and ... education markets.  Zygote maintains the world,s most comprehensive ... and has pioneered development of high-end solid 3D ...
(Date:10/31/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ... on the development of oral drug delivery systems, ... call to discuss the clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... a.m. Eastern time. Shareholders and other ...
(Date:10/31/2014)...  Zacks.com announces the list of stocks featured in the Analyst ... news and events impacting stocks and the financial markets. Stocks recently ... - Free Report ), Celgene (Nasdaq: CELG - ... Free Report ), Market Vectors Biotech ETF (AMEX: BBH ... XBI - Free Report ). Today, ...
Breaking Medicine Technology:Zebra Imaging and Zygote Media Partner to Bring 3D Visualization to the Medical Community 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7
... - ViziLite Plus with TBlue630 -, PHOENIX, Sept. ... with Tblue630(TM) screening system for early detection of,abnormalities which ... identify,pre-cancerous lesions in a Phase II study of Cetuximab ... developed by ImClone,Systems (Nasdaq: IMCL ) and distributed ...
... Secondary Endpoints, San Carlos, Calif., Sept. 4 ... company focused on developing novel,pain management therapies, today ... of NGX-4010, the Company,s dermal patch containing,the TRPV1 ... postherpetic,neuralgia (PHN). The study, a multi-center, double-blind, controlled ...
Cached Medicine Technology:Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 2Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 3NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 2NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 3NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 4NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 5NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 6NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 7
The Hypervisor VI is a solution for telemetry, LAN and wireless LAN networking. It includes bi-directional communication with Mindray bedside patient monitors and can store waveforms and numeric info...
DS 7600 Central Station...
... DLE (Drug List Editor) Multi-Channel Infusion System ... technology. The instrument combines three independent infusion ... in an unparalleled small size. Now with ... Infusion System simplifies the delivery of complex ...
... SRS Freedom Chart Manager provides powerful workflow ... order management, integrated transcription services, and customized ... engine that eliminates the need for paper ... benefits of a paperless office now and ...
Medicine Products: